Glaukos Corp
NYSE:GKOS

  • LAST PRICE
    125.5000
  • TODAY'S CHANGE (%)
    -0.2400 (-0.1909%)
  • Bid / Lots
    122.0000/ 3
  • Ask / Lots
    200.8100/ 2
  • Open / Previous Close
    124.7800 / 125.7400
  • Day Range
    123.9300
    126.1300
  • 52 Week Range
    59.2200
    136.6050
  • Volume
    515,311

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Recent News

0 New Today

Medical Equipment, Supplies & Distribution Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
GKOS
Glaukos Corp
6.9B
-39.2x
---
INSP
Inspire Medical Systems Inc
6.3B
1,067.6x
---
LNTH
Lantheus Holdings Inc
6.9B
16.7x
+35.30%
STVN
Stevanato Group SpA
6.1B
39.8x
---
RGEN
Repligen Corp
8.2B
-3,446.3x
+15.08%
PEN
Penumbra Inc
7.9B
592.4x
+65.82%
As of 2024-09-11

Company Information

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Contact Information

Headquarters
1 GLAUKOS WAYALISO VIEJO, CA, United States 92656
Phone
949-367-9600
Fax
949-367-9984

Executives

Chairman of the Board, Chief Executive Officer
Thomas Burns
President, Chief Operating Officer
Joseph Gilliam
Chief Financial Officer, Senior Vice President
Alex Thurman
Chief Development Officer
Tomas Navratil
Lead Independent Director
Mark Foley

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$6.9B
Revenue (TTM)
$341.7M
Shares Outstanding
55.0M
Glaukos Corp does not pay a dividend.
Beta
1.04
EPS
$-3.20
Book Value
$9.40
P/E Ratio
-39.2x
Price/Sales (TTM)
20.2
Price/Cash Flow (TTM)
---
Operating Margin
-39.70%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.